Entrada Therapeutics (TRDA) Competitors $9.13 +0.19 (+2.13%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRDA vs. OCUL, DYN, ARDX, CALT, IOVA, AMPH, SNDX, ADPT, BGM, and AUPHShould you be buying Entrada Therapeutics stock or one of its competitors? The main competitors of Entrada Therapeutics include Ocular Therapeutix (OCUL), Dyne Therapeutics (DYN), Ardelyx (ARDX), Calliditas Therapeutics AB (publ) (CALT), Iovance Biotherapeutics (IOVA), Amphastar Pharmaceuticals (AMPH), Syndax Pharmaceuticals (SNDX), Adaptive Biotechnologies (ADPT), Qilian International Holding Group (BGM), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry. Entrada Therapeutics vs. Ocular Therapeutix Dyne Therapeutics Ardelyx Calliditas Therapeutics AB (publ) Iovance Biotherapeutics Amphastar Pharmaceuticals Syndax Pharmaceuticals Adaptive Biotechnologies Qilian International Holding Group Aurinia Pharmaceuticals Ocular Therapeutix (NASDAQ:OCUL) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, dividends, profitability, earnings, media sentiment, valuation and risk. Does the MarketBeat Community favor OCUL or TRDA? Ocular Therapeutix received 421 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 84.00% of users gave Entrada Therapeutics an outperform vote while only 70.27% of users gave Ocular Therapeutix an outperform vote. CompanyUnderperformOutperformOcular TherapeutixOutperform Votes44270.27% Underperform Votes18729.73% Entrada TherapeuticsOutperform Votes2184.00% Underperform Votes416.00% Do analysts recommend OCUL or TRDA? Ocular Therapeutix presently has a consensus target price of $16.38, indicating a potential upside of 97.29%. Entrada Therapeutics has a consensus target price of $25.67, indicating a potential upside of 181.12%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Entrada Therapeutics is more favorable than Ocular Therapeutix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the media refer more to OCUL or TRDA? In the previous week, Ocular Therapeutix had 8 more articles in the media than Entrada Therapeutics. MarketBeat recorded 10 mentions for Ocular Therapeutix and 2 mentions for Entrada Therapeutics. Ocular Therapeutix's average media sentiment score of 0.98 beat Entrada Therapeutics' score of 0.86 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entrada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of OCUL or TRDA? 59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 3.5% of Ocular Therapeutix shares are owned by insiders. Comparatively, 7.6% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, OCUL or TRDA? Ocular Therapeutix has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Which has stronger valuation & earnings, OCUL or TRDA? Entrada Therapeutics has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$63.72M20.71-$80.74M-$1.26-6.59Entrada Therapeutics$210.78M1.63-$6.68M$1.914.78 Is OCUL or TRDA more profitable? Entrada Therapeutics has a net margin of 25.53% compared to Ocular Therapeutix's net margin of -283.74%. Entrada Therapeutics' return on equity of 16.11% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-283.74% -45.18% -30.87% Entrada Therapeutics 25.53%16.11%10.39% SummaryEntrada Therapeutics beats Ocular Therapeutix on 13 of the 19 factors compared between the two stocks. Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRDA vs. The Competition Export to ExcelMetricEntrada TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$343.24M$6.89B$5.57B$7.83BDividend YieldN/A3.06%5.11%4.21%P/E Ratio5.747.4422.4418.48Price / Sales1.63242.73394.10103.59Price / CashN/A65.8538.1834.62Price / Book1.266.516.774.25Net Income-$6.68M$143.21M$3.22B$248.23M7 Day Performance1.90%1.98%1.48%0.89%1 Month Performance4.22%6.89%3.99%3.53%1 Year Performance-31.09%-2.52%16.20%5.08% Entrada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRDAEntrada Therapeutics2.8772 of 5 stars$9.13+2.1%$25.67+181.1%-23.0%$343.24M$210.78M5.74110Upcoming EarningsNews CoverageOCULOcular Therapeutix3.5926 of 5 stars$8.13+5.4%$16.38+101.4%+75.1%$1.29B$63.72M-6.16230Upcoming EarningsNews CoverageDYNDyne Therapeutics3.3305 of 5 stars$11.28+2.0%$47.46+320.8%-53.4%$1.28BN/A-3.17100Upcoming EarningsShort Interest ↑News CoverageARDXArdelyx4.5081 of 5 stars$5.35+1.7%$10.61+98.3%-13.9%$1.28B$333.62M-33.4490Upcoming EarningsCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180IOVAIovance Biotherapeutics4.5549 of 5 stars$3.61+2.8%$18.22+404.8%-69.5%$1.18B$164.07M-2.42500Upcoming EarningsGap DownAMPHAmphastar Pharmaceuticals4.5062 of 5 stars$24.41+0.9%$43.50+78.2%-40.8%$1.16B$731.97M8.141,620Upcoming EarningsPositive NewsSNDXSyndax Pharmaceuticals3.6294 of 5 stars$13.42+0.7%$36.20+169.7%-33.0%$1.15B$23.68M-3.70110Upcoming EarningsPositive NewsADPTAdaptive Biotechnologies4.1493 of 5 stars$7.77-1.6%$9.40+21.0%+180.9%$1.15B$178.96M-7.13790Upcoming EarningsNews CoveragePositive NewsGap DownBGMQilian International Holding GroupN/A$11.27+1.6%N/AN/A$1.10B$25.10M0.00298AUPHAurinia Pharmaceuticals2.633 of 5 stars$8.00-2.2%$11.50+43.8%+61.9%$1.09B$235.13M-53.33300Positive News Related Companies and Tools Related Companies Ocular Therapeutix Alternatives Dyne Therapeutics Alternatives Ardelyx Alternatives Calliditas Therapeutics AB (publ) Alternatives Iovance Biotherapeutics Alternatives Amphastar Pharmaceuticals Alternatives Syndax Pharmaceuticals Alternatives Adaptive Biotechnologies Alternatives Qilian International Holding Group Alternatives Aurinia Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRDA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TRDA Stock Free TRDA Stock Alerts